To include your compound in the COVID-19 Resource Center, submit it here.

Syros prioritizing oral CDK7, dropping IV after Phase I data

After tolerability issues in a Phase I trial led to lower doses and longer infusion times for its first clinical CDK7 inhibitor, Syros is choosing to concentrate instead on a preclinical oral compound aimed at the same target.

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) intends to start next quarter a Phase I trial in select solid tumors of SY-5609, its non-covalent oral

Read the full 591 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE